Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

CONCLUSIONS: Amongst patients with T2DM, recent ACS, and a moderate-to-high likelihood of advanced liver fibrosis, apabetalone was associated with a significantly lower rate of ischemic MACE and HHF and attenuated the increase in hepatic FS over time.PMID:36039183 | PMC:PMC9419281 | DOI:10.1016/j.ajpc.2022.100372

Source: Atherosclerosis - August 30, 2022 Category: Cardiology Authors: Peter P Toth Gregory G Schwartz Stephen J Nicholls Aziz Khan Michael Szarek Henry N Ginsberg Jan O Johansson Kamyar Kalantar-Zadeh Ewelina Kulikowski Ken Lebioda Norman C W Wong Michael Sweeney Kausik K Ray BETonMACE Investigators Source Type: research